ulixertinib: Clinical Trials

11 trials of ulixertinib, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

4 active not recruiting, 3 terminated, 2 completed, 2 recruiting. 11 Phase 2, 3 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 211Active not recruiting 4, Terminated 3, Completed 2, Recruiting 2
Phase 13Completed 2, Recruiting 1

Follow ulixertinib: new trials by email Literature Review of ulixertinib trials Research Report on ulixertinib

Trials (filtered) newest first · largest first

All 11 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study of Ruxolitinib in Combination With Ulixertinib in People With Myelofibrosis
Ulixertinib, Ruxolitinib - Myelofibrosis
Phase 1 / Phase 2RecruitingMemorial Sloan Kettering Cancer Center372025-01-072026-07-28
Ulixertinib in People With Histiocytic Neoplasms
Ulixertinib - Histiocytic Neoplasms
Phase 2RecruitingMemorial Sloan Kettering Cancer Center382024-05-072026-10-15
Trial of Ulixertinib in Combination With Hydroxychloroquine in Patients With Advanced Gastrointestinal (GI) Malignancies
Ulixertinib, Hydroxychloroquine - Tumor, Solid, Gastrointestinal Cancer
Phase 2TerminatedBioMed Valley Discoveries, Inc472022-05-262025-09-25
Study of Ulixertinib for Patients With Advanced Malignancies Harboring MEK or Atypical BRAF Alterations
Ulixertinib, Physician's Choice - Advanced Solid Tumor, BRAF Gene Mutation
Phase 2TerminatedBioMed Valley Discoveries, Inc1042021-01-072024-06-04
Testing BVD-523FB (Ulixertinib) as Potentially Targeted Treatment in Cancers With Genetic Changes (MATCH - Subprotocol Z1L)
Biopsy Procedure, Biospecimen Collection, Computed Tomography - Advanced Lymphoma, Advanced Malignant Solid Neoplasm
Phase 2Active not recruitingNational Cancer Institute (NCI)352019-07-242026-10-15
Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)
Pharmacokinetic Study, Ulixertinib - Advanced Malignant Solid Neoplasm, Recurrent Ependymal Tumor
Phase 2Active not recruitingNational Cancer Institute (NCI)202018-11-142026-11-13
A Phase II Study of BVD-523 in Metastatic Uveal Melanoma
BVD-523 - Uveal Melanoma
Phase 2TerminatedDana-Farber Cancer Institute132018-03-262026-07-27
Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)
Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration and Biopsy - Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Non-Hodgkin Lymphoma
Phase 2Active not recruitingNational Cancer Institute (NCI)13772017-07-312026-11-13
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Adavosertib, Afatinib, Afatinib Dimaleate - Advanced Lymphoma, Advanced Malignant Solid Neoplasm
Phase 2Active not recruitingNational Cancer Institute (NCI)64522015-08-172026-11-12
Phase 1/2 Study of the ERK1/2 Inhibitor BVD-523 in Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndromes
BVD-523 - Acute Myelogenous Leukemia, Myelodysplastic Syndrome
Phase 1 / Phase 2CompletedBioMed Valley Discoveries, Inc532014-11-012019-01-29
Phase I Dose-Escalation, Safety, Pharmacokinetic and Pharmacodynamic Study of BVD-523 in Patients With Advanced Malignancies
BVD-523 - Advanced Solid Tumors
Phase 1 / Phase 2CompletedBioMed Valley Discoveries, Inc1362013-03-012020-03-20

Conditions studied

Glioma (3)  ·  Ependymoma (2)  ·  Hepatoblastoma (2)  ·  Histiocytosis, Langerhans-Cell (2)  ·  Lymphoma (2)  ·  Lymphoma, Non-Hodgkin (2)  ·  Medulloblastoma (2)  ·  Multiple Myeloma (2)  ·  Neuroblastoma (2)  ·  Neuroectodermal Tumors, Primitive, Peripheral (2)  ·  Osteosarcoma (2)  ·  Rhabdoid Tumor (2)  ·  Rhabdomyosarcoma (2)  ·  Sarcoma (2)  ·  Sarcoma, Ewing (2)

Sponsors

BioMed Valley Discoveries, Inc (4)  ·  National Cancer Institute (NCI) (4)  ·  Memorial Sloan Kettering Cancer Center (2)  ·  Dana-Farber Cancer Institute (1)

Countries

United States (11)  ·  Puerto Rico (3)  ·  Australia (1)  ·  Canada (1)  ·  Guam (1)

Top investigators

Donald W Parsons (1)  ·  Eli Diamond, MD (1)  ·  F. Stephen Hodi, MD (1)  ·  Keith T Flaherty (1)  ·  Kieuhoa T Vo (1)  ·  Raajit Rampal, MD, PhD (1)  ·  Vivek Subbiah (1)

Results publications

PMID 28939558, PMID 26586415, PMID 29603015, PMID 31401903, PMID 32463741, PMID 33048619, PMID 33389388, PMID 33591402, PMID 35133871, PMID 35138919, PMID 35353553, PMID 36351402, PMID 37053535, PMID 37322121, PMID 37934000, PMID 38591867, PMID 38935895, PMID 39666929, PMID 39693587, PMID 39913886, PMID 40865033, PMID 41066729, PMID 41166674, PMID 42686334

NIH funding

U10CA180820 (2), U10CA180886 (2), U24CA196172 (1)